Ibnova develops vascularized engineered heart tissue patches to repair damaged myocardium in patients with advanced heart failure. By integrating living cardiac cells with a supportive vascular network, their patches aim to restore contractile function where drugs and devices are insufficient, targeting the millions worldwide who face poor long‑term survival after heart disease.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced heart failure patients often experience irreversible loss of myocardial tissue, and existing drugs and devices only manage symptoms without restoring lost heart muscle. This leads to high mortality rates, with 45–60% of patients dying within five years of diagnosis, and limited therapeutic options for those who do not respond to current treatments.
Solution
Ibnova is developing vascularized engineered heart tissue (EHT) patches that can be surgically applied to damaged myocardium to replace lost muscle and restore contractile function. The patches incorporate functional blood vessels, enabling rapid perfusion and integration with the host circulatory system, which supports cell survival and tissue maturation after implantation. By delivering living cardiac cells within a pre-vascularized scaffold, the therapy aims to improve cardiac output and long‑term survival for patients with end‑stage heart failure who have exhausted conventional medical and device therapies. The platform is designed for scalable manufacturing and regulatory compliance to facilitate clinical translation.
Target Audience
Primary customers are cardiovascular surgeons and heart failure treatment centers seeking regenerative therapies for patients with advanced, drug‑refractory heart failure.
Features
- Pre‑vascularized cardiac tissue constructs that include endothelial networks for immediate perfusion post‑implantation
- Human pluripotent stem cell‑derived cardiomyocytes organized in a biomimetic scaffold to generate contractile force
- GMP‑compatible manufacturing process with defined cell sourcing, scaffold material qualification, and process‑locking protocols
- Integrated analytical assays to assess tissue viability, electrophysiological function, and vascular integration before release
- Surgical delivery format compatible with standard open‑heart or minimally invasive implantation techniques